Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of life-threatening infections. The company’s lead product candidate, TR-701 is a novel oral and IV oxazolidinone antibiotic with potent activity against Gram positive bacterial pathogens. Trius’ pipeline includes three additional structure-based drug design programs directed against novel antibacterial targets.